Gene Therapy News and Research

RSS

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery.

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

AMT, Amgen amend GDNF gene license agreement

Amsterdam Molecular Therapeutics Holding N.V., a leader in the development of gene-based therapies, today announced that it has amended and restated its licensing agreement with Amgen for gene therapy applications incorporating the GDNF (glial cell derived neurotrophic factor) gene, to which Amgen holds rights. Financial terms were not disclosed.

2 Dec 2010

Wake Forest University to begin clinical trial for low-grade gliomas

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

2 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Ageing reversed in mice: Study

A scientific team at Harvard-affiliated medical centers genetically manipulated mice to age faster. Then they used gene therapy to lengthen telomeres. Telomeres are compounds found at the ends of strands of DNA that are related to age. This lengthening of telomeres reversed age-related problems such as decreased brain function and infertility.

29 Nov 2010

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

QIAGEN has been selected to contribute to the fight against infectious diseases in animals in emerging countries by supplying an international pilot project associated with the United Nations with portable devices to perform ultra-fast molecular testing in the field.

From QIAGEN Manchester Limited 29 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood.

24 Nov 2010

Researcher develops new method that causes cancer cells to self-destruct

Tulane University researcher W T. Godbey has developed a treatment for cancer using a method that causes cancer cells to self-destruct while sparing surrounding healthy cells.

23 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Sangamo BioSciences, Inc. announced today the presentation of Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509, a zinc finger protein transcriptional activator (ZFP-TF) of the vascular endothelial growth factor (VEGF)-A gene as a treatment for ALS.

17 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 12-month data from its Phase 2 CUPID clinical trial of MYDICAR demonstrated significant improvements in clinical outcomes and key disease markers in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

15 Nov 2010

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2010.

15 Nov 2010

CEVEC establishes North American subsidiary in Maryland, USA

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the US expansion of it's business by founding a North American subsidiary, CEVEC Pharmaceuticals, Inc., in Potomac, Maryland, USA.

15 Nov 2010

Neurologix third quarter net loss decreases to $2.3 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Grand Challenges Explorations projects receive new grants for tuberculosis research

Weill Cornell Medical College announced today that it was awarded two $100,000 grants from the Bill & Melinda Gates Foundation as part of the next phase of Grand Challenges Explorations, an initiative to encourage bold and unconventional ideas for global health.

10 Nov 2010

Research report on current and evolving technologies in drug delivery

The drug delivery market is a rapidly evolving force in the pharmaceutical industry. Within this segment injectables have a significant role to play at present with the increasing use of proteins and peptides.

9 Nov 2010

Gene Therapy News and Research

Further Reading

Research findings could provide breakthrough for development of effective therapies for NSCLC

AMT, Amgen amend GDNF gene license agreement

Wake Forest University to begin clinical trial for low-grade gliomas

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

Ageing reversed in mice: Study

QIAGEN to supply point-of-need molecular veterinary diagnostics for disease detection in emerging countries

New strategy to prevent memory deficits in mouse model with AD

Hepcidin hormone may be potential therapeutic tool for anemic blood disorders

Researcher develops new method that causes cancer cells to self-destruct

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Sangamo presents Phase 2 clinical data in ALS at Society for Neuroscience Meeting

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Celladon’s Phase 2 CUPID trial shows improved clinical outcomes in advanced heart failure patients

Inovio third quarter total revenue decreases from $3.6 million to $1.3 million

CEVEC establishes North American subsidiary in Maryland, USA

Neurologix third quarter net loss decreases to $2.3 million

Scientists unveil mechanism of liver regeneration

Grand Challenges Explorations projects receive new grants for tuberculosis research

Research report on current and evolving technologies in drug delivery

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News